Inaugural H. D. Smith & NAPPSA Scholarship award goes to University of Kentucky student
SPRINGFIELD, Ill. — H.D. Smith and the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas on Monday awarded the inaugural H. D. Smith & NAPPSA Scholarship to Oreoluwa Adedoyin.
Pharmacy students affiliated with the NAPPSA vied for a $1,000 scholarship as a part of an inaugural program sponsored by H. D. Smith for NAPPSA’s qualifying student members. “This scholarship program promotes a bright future for our young Nigerian pharmacists and brings our partnership with H. D. Smith to a new level,” stated Emmanuel Ezirim, NAPPSA board member and business to business coordinator.
“We are pleased to offer this program through our partnership with NAPPSA to recognize the efforts of promising and accomplished pharmacy students who will impact the future of community pharmacy,” Rob Meriweather, H. D. Smith director national accounts retail sales, said.
Eligible applicants were required to be enrolled in a Pharm.D. or graduate program relevant to pharmaceutical sciences in a university in the United States and had to be considered in good standing as defined by the educational institution. Applicants were asked to provide an essay reflecting on why the applicant believed he or she should be selected.
Oreoluwa Adedoyin of the University of Kentucky was awarded the scholarship. Oreoluwa is studying Pharmaceutical Sciences and holds a GPA above 3.85. She will use the funds towards school materials and to attend the 2014 NAPPSA meeting.
“We believe that Oreoluwa emulates all the desired aspects of the winner, and more importantly, that of a community pharmacist of the future,” noted Adeboye Adejare, chairman of the NAPPSA Scholarship Award Committee.
Actavis divests China subsidiary
DUBLIN — Actavis last week announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co. to acquire Actavis’ interest in Actavis (Foshan) Pharmaceuticals Co., an Actavis subsidiary based in Foshan, China.
Actavis intends to continue further commercial operations in China in collaboration with its preferred business partners.
"Actavis is focused on strengthening our investment in high-growth markets where our size and scale allow us to maintain a competitive presence with the leading companies in the market," Sigurdur Oli Olafsson, president, Actavis Pharma, said. "Our operations in Foshan were limited in scope and we believe that their value will be better capitalized on by Chiral, which will add manufacturing and marketing capabilities allowing them to expand their portfolio and strengthen their position in the Chinese market."
Purdue Pharma names president and CEO
STAMFORD, Conn. — Purdue Pharma on Monday named Mark Timney as president and CEO.
"We found a proven leader in Mark Timney," said Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue’s culture of excellence, will grow our business and strengthen our healthcare industry leadership."
Timney brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Prior to joining Purdue, he was president of Merck US, where he managed sales and marketing, managed markets and payers.
With Timney’s guidance, Purdue will continue advancing research and development initiatives and pioneering new commercial models.
Before coming to the United States, Timney served for seven years as Merck’s country manager in Korea and then Japan. Prior to that, he held leadership positions for more than four years at Merck Australia. Before joining Merck, he spent eight years in sales and marketing at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia and Roussel Labs in the United Kingdom.
Timney succeeds John Stewart, who has retired from Purdue.